Chile’s Supply Center for the National System of Health Services (Cenabast), which negotiates the purchase of medicines for offices and public hospitals in the country, may have been over-charged by up to 35% as a result of price-fixing. This was one of the core points presented in the request by the National Economic Prosecutor’s Office (FNE) against the Fresenius Kabi Chile laboratories, its subsidiary Sanderson, and Biosano, for agreeing to an alleged pact to affect the results of public tenders between 1999 and the first half of 2013.
The head of the FNE’s litigation division, Víctor Santelices, emphasized that it was a unique agreement that affected 93 medicines tendered in 1,262 separate cases. The lawyer said that a report by the entity had shown that, over the period in which the alleged agreement was in place, there was a price premium in the purchase of medicines that ranged between 18% and 35%.
The lawyer of Cenabast, Leonardo Corral, concurred regarding the existence of collusion between the laboratories and indicated that the extra benefit perceived by the accused represented an important cost for the State, as a result of the increase in public expenditure.
Sanderson’s attorney and Carey study partner, Claudio Lizana, criticized the probative value of Biosano’s leniency-seeking whistle-blowing and rejected the injunction. “We believe that this honorable court does have the faculties apply the law and to determine if the contribution of Biosano was adjusted correctly, otherwise the resolution of the national economic prosecutor would be impregnable,” he said.
Full Content: Economía y Negocios
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
FTC Pushes Review of CoStar’s Commercial Real Estate Antitrust Case
Jan 31, 2024 by
CPI
UK’s CMA Investigates Ardonagh’s Atlanta Group and Markerstudy Merger
Jan 31, 2024 by
CPI
Greenberg Traurig Grow Financial Regulatory and Compliance Practice
Jan 31, 2024 by
CPI
Dutch Regulator Fines Uber €10 Million for Privacy Violations
Jan 31, 2024 by
CPI
DOJ Investigates AI Competition, Eyes Microsoft’s OpenAI Deal: Bloomberg
Jan 31, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – The Rule(s) of Reason
Jan 29, 2024 by
CPI
Evolving the Rule of Reason for Legacy Business Conduct
Jan 29, 2024 by
CPI
The Object Identity
Jan 29, 2024 by
CPI
In Praise of Rules-Based Antitrust
Jan 29, 2024 by
CPI
The Future of State AG Antitrust Enforcement and Federal-State Cooperation
Jan 29, 2024 by
CPI